A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)
This study is testing a new experimental medicine called DZD6008 to see how well it fights a specific type of advanced lung cancer. The goal is to see if this treatment can safely stop cancer cells from growing in people whose tumors have specific gene changes.
This study is for adults aged 18 and older with advanced non-small cell lung cancer that has specific EGFR gene mutations. You must have a confirmed diagnosis and be able to provide a sample of your tumor tissue for the study team to test.
Participants will receive the study medication and undergo regular health check-ups to monitor how the drug affects the cancer and how the body reacts to it. The team will closely watch for any side effects to ensure your safety throughout the process.
The study is currently recruiting volunteers and is taking place at medical centers in New York, New York, and Fairfax, Virginia. Please contact your doctor or the study team to see if there is an opening that fits your needs.
- 1This is a Phase 1 study, meaning it is an early-stage test focused on safety.
- 2The treatment targets specific genetic mutations common in this type of lung cancer.
- 3You will need to share previous medical records and tumor samples to confirm you are a good match.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.